Group 1 - Junshi Bioscience (01877) shares rose over 10%, currently up 11.03% at HKD 34.22, with a trading volume of HKD 516 million [1] - The company announced that its subsidiary, Shanghai Juntao Biopharmaceutical Technology Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of JT118 injection, a "dual" recombinant protein vaccine aimed at preventing monkeypox virus infection [1] - Preclinical studies indicate that JT118 shows significant protective effects against vaccinia virus/monkeypox virus infections in small animal models, with good safety profiles [1] Group 2 - The 2025 World Lung Cancer Conference (WCLC) will be held from September 6 to 9, 2025, in Barcelona, Spain [1] - Junshi Bioscience's innovative products, including anti-BTLA monoclonal antibody tifcemalimab and anti-PD-1 monoclonal antibody teriprizumab, have multiple research results selected for oral presentations and posters at the conference, showcasing the latest advancements in lung cancer research [1]

Core Viewpoint - Junshi Biosciences (01877) announced that its subsidiary, Shanghai Juntao Biopharmaceutical Technology Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial application of JT118 injection, a recombinant protein vaccine aimed at preventing monkeypox virus infection [1] Group 1: Product Details - JT118 is a "two-in-one" recombinant protein vaccine composed of monkeypox virus antigens A35 (extracellular membrane virus antigen) and M1 (intracellular mature virus antigen) [1] - The vaccine retains the epitope structures of both natural antigens A35 and M1 while significantly increasing molecular weight through multi-antigen fusion, which enhances immune activation [1] Group 2: Clinical Research Findings - Preclinical studies indicate that JT118 can generate high levels of binding antibodies, vaccinia virus/monkeypox virus neutralizing antibodies, and cellular immune activation in both small and large animal models [1] - The vaccine demonstrates significant protective effects against vaccinia virus/monkeypox virus infections in animal models, with good safety profiles [1]

Core Viewpoint - The company has received approval for clinical trials of its recombinant protein vaccine JT118, aimed at preventing monkeypox virus infection, marking a significant step in its vaccine development efforts [1][2]. Group 1: Clinical Trial Approval - The company's subsidiary, Shanghai JunTuo Biopharmaceutical Technology Co., Ltd., has obtained the clinical trial approval notice from the National Medical Products Administration for JT118 [1]. - JT118 is a "two-in-one" recombinant protein vaccine composed of monkeypox virus antigens A35 and M1, designed to enhance immune response [1]. Group 2: Vaccine Development and Research - Preclinical studies indicate that JT118 can generate high levels of neutralizing antibodies and activate cellular immunity in animal models, demonstrating significant protective effects against monkeypox virus infection [1]. - The company has formed collaborations with several prestigious institutions, including Peking University and the Chinese Academy of Sciences, to jointly develop the monkeypox recombinant protein vaccine [2]. - As of the announcement date, no vaccines for preventing monkeypox virus infection have been approved for market release in China [2].

Core Viewpoint - Junshi Biosciences (688180.SH) announced that its subsidiary, Shanghai Juntao Biopharmaceutical Technology Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of JT118 injection, aimed at preventing monkeypox virus infection [1] Group 1: Company Developments - The clinical trial application for JT118 injection has been approved, allowing the company to conduct trials for its use against monkeypox virus [1] - JT118 is a "two-in-one" recombinant protein vaccine composed of monkeypox virus antigens A35 (extracellular membrane virus antigen) and M1 (intracellular mature virus antigen) [1] - The vaccine retains the structural epitopes of both natural antigens A35 and M1 while significantly increasing molecular weight through multi-antigen fusion, enhancing immune response [1] Group 2: Industry Context - Monkeypox is a zoonotic viral disease caused by the monkeypox virus, classified under the Orthopoxvirus genus of the Poxviridae family [1] - The monkeypox virus replicates in two different forms: extracellular membrane virus and intracellular mature virus, both of which are infectious [1]